Company intelligence / Profile preview
Hangzhou DAC Biotech
Hangzhou, Zhejiang, Chinadacbiotech.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Hangzhou DAC Biotech has a broad pipeline of over 20 ADC drugs, with at least five in clinical development. Lead programs have reached up to Phase 2 trials, targeting advanced cancers such as HER2-positive breast cancer and small cell lung cancer. The company’s CPT113 platform is designed for next-generation ADC capabilities, including site-specific conjugation and high-potency payloads. Clinical results are not yet published in detail but the company is advancing multiple assets through early-stage trials
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugateSmall molecule (as payloads within ADCs)Monoclonal antibody (as part of ADCs)
- Industry
- Biotech
02
Drug pipeline
32 assets31 more assets in the full pipeline.
03
Partnerships
Janssen Biotech / Johnson & Johnson Innovation – JJDC, Inc.WuXi BiologicsAadi Bioscience
Beyond the preview
Go deeper on Hangzhou DAC Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hangzhou DAC Biotech.